CSN5, a key COP9 signalosome subunit, regulates protein stability in the cell cycle, apoptosis and DNA repair. Its overexpression in cancer promotes tumor growth, metastasis and therapy resistance, making it a potential therapeutic target.
Perimeter Medical Imaging AI Inc. secured FDA premarket approval for Claire, its AI-powered imaging device which detects difficult-to-see cancer during breast-conserving surgery. Claire combines AI with wide-field optical coherence tomography to provide surgeons with high-resolution, real-time views of excised tumor margins, to reduce the need for re-operations.
Approximately 10%-15% of breast cancer cases are classified within the invasive lobular carcinoma (ILC) type, and a great majority of them are estrogen receptor-positive (ER+). Despite the significant clinical differences between ILCs and invasive carcinoma of no special type (or ductal), ICL treatment still follows ductal paradigms, relying on endocrine therapy plus surgery and radiotherapy.
In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.
Calidi Biotherapeutics Inc. recently presented data regarding CLD-401 as an immunotherapeutic approach developed using the Redtail gene therapy platform. This platform uses a tumor-specific, replicating enveloped vaccinia virus that expresses a chimeric form of CD55 to allow complement and neutralizing antibody resistance, as well as systemic administration.
Researchers from the Innovation Program of Drug Research on Inflammatory and Immune Diseases at NMPA Key (China) and collaborators aimed to further investigate the impact of Src homology phosphatase 2 (SHP2) on breast cancer-induced bone destruction.
In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.
Researchers from Jiangsu Ocean University reported the synthesis and preclinical evaluation of novel derivatives of SKF-83566, a selective D1 receptor antagonist widely used in dopamine signaling research.
Triple-negative breast cancer (TNBC) cells depend on the transcriptional kinases CDK12 and CDK13 to maintain DNA damage response gene expression and manage replication stress. Due to their functional overlap, inhibition of a single kinase may permit compensatory activity.
